LCAT Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of LCAT monoclonal antibodies for research in lipid metabolism and cardiovascular health. LCAT Antibodies are optimized for various applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Lecithin-cholesterol acyltransferase (LCAT) plays a crucial role in the metabolism of lipoproteins, facilitating the conversion of free cholesterol into cholesteryl esters, which are essential for maintaining lipid homeostasis. LCAT is significant in the regulation of high-density lipoprotein (HDL) levels and is implicated in various cardiovascular diseases. Understanding LCAT function is vital for developing therapeutic strategies aimed at managing dyslipidemia and associated conditions. Researchers can explore the complex relationship between LCAT and cardiovascular health through detailed molecular studies. Advanced research techniques enable scientists to examine LCAT's role in cholesterol transport and metabolism. The relationship between LCAT and HDL metabolism continues to be an active area of investigation in cardiovascular research. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing our understanding of lipid metabolism and cardiovascular disease mechanisms.